Stryker (NYSE:SYK) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Stryker from "hold" to "buy"; the stock has a consensus "Moderate Buy" with 16 Buy vs. 6 Hold ratings and an average price target of $401.43.
• Stryker missed Q1 estimates (EPS $2.60 vs. ~$2.98; revenue $6.02B vs. ~$6.34B) after a cyber incident that disrupted production, sending shares down ~6.3%, though management kept its FY‑2026 guidance at $14.90–$15.10 EPS.
• Insider selling was notable — director Ronda E. Stryker sold 250,000 shares (~$90.7M) in February — while institutional ownership is high (~77%) and several large funds recently increased stakes.

Stryker (NYSE:SYK - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

Several other analysts have also weighed in on SYK. Barclays reiterated an "overweight" rating and issued a $469.00 price objective on shares of Stryker in a research note on Monday, February 2nd. Raymond James Financial upgraded shares of Stryker from a "market perform" rating to an "outperform" rating and set a $418.00 price objective for the company in a research note on Tuesday, January 6th. Piper Sandler reiterated an "overweight" rating on shares of Stryker in a research note on Tuesday, January 27th. Jefferies Financial Group reiterated a "buy" rating and issued a $465.00 price objective on shares of Stryker in a research note on Wednesday, March 4th. Finally, TD Cowen lowered shares of Stryker from a "buy" rating to a "hold" rating and set a $387.00 price objective for the company. in a research note on Monday, January 26th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $401.43.

Stryker Trading Down 6.3%

SYK opened at $295.43 on Friday. The company's 50 day moving average is $345.67 and its 200-day moving average is $356.95. Stryker has a 1-year low of $294.55 and a 1-year high of $404.87. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The company has a market cap of $113.15 billion, a P/E ratio of 35.17, a PEG ratio of 1.84 and a beta of 0.80.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.74% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the prior year, the business earned $2.84 earnings per share. The firm's quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts predict that Stryker will post 14.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of the business's stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares of the company's stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.60% of the company's stock.

Hedge Funds Weigh In On Stryker

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank purchased a new stake in Stryker during the fourth quarter valued at about $1,822,272,000. Auto Owners Insurance Co lifted its holdings in Stryker by 35,047.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company's stock valued at $1,024,444,000 after purchasing an additional 2,906,448 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company's stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares during the last quarter. Corient Private Wealth LLC lifted its holdings in Stryker by 104.4% during the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company's stock valued at $887,525,000 after purchasing an additional 1,146,998 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company's stock valued at $2,342,987,000 after purchasing an additional 741,542 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY‑2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer‑term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near‑term upside expectations and add selling pressure. Article Title

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.